BioAge reveals positive Phase 1 NLRP3 data, cash runway extended through 2029
BioAge Labs (NASDAQ:BIOA) today reported its financial results for the full year ended December 31, 2025, marking a pivotal transition from early-stage discovery to a high-conviction clinical platform.





-640x360.webp&w=3840&q=75)




